Demis Hassabis, chief of DeepMind spinout Isomorphic Labs, believes the company would halve drug discovery times after inking deals with Eli Lilly and Novartis
Chief of Google's AI unit and Isomorphic Labs spells out targets following $3bn Eli Lilly-Novartis partnerships X: @kymawhite . Forums: Slashdot X: Kimberly White / @kymawhite : Thanks to the team at the @FT for covering the latest developments @IsomorphicLabs and our new collaborations w/@EliLillyandCo and @Novartis. https://www.ft.com/... Forums: Msmash / Slashdot : DeepMind Spin-off Aims To Halve Drug Discovery Times Following Big Pharma Deals